SCM
SAGE

Sterling Capital Management’s Sage Therapeutics SAGE Stock Holding History

Sterling Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,464
Closed -$13.4K – 3282
2025
Q2 		$13.4K Buy
1,464
+522
+55% +$3.84K ﹤0.01% 1960
2025
Q1 		$7.49K Sell
942
-808
-46% -$5.92K ﹤0.01% 1974
2024
Q4 		$9.5K Buy
1,750
+1,561
+826% +$9.54K ﹤0.01% 2180
2024
Q3 		$1.36K Buy
+189
New +$1.73K ﹤0.01% 2377
2016
Q1 		– Sell
-5,113
Closed -$298K – 977
2015
Q4 		$298K Buy
+5,113
New +$253K ﹤0.01% 871

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Sterling Capital Management's SAGE Position: Q3 2025 in Review

Sterling Capital Management sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 1,464 shares — an estimated $13.4K sold.

Sterling Capital Management first reported a position in SAGE in Q4 2015 and held it in 5 quarters. The position peaked at $298K in Q4 2015. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • Sterling Capital Management reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Sterling Capital Management sold 1,464 Sage Therapeutics shares in Q3 2025, an estimated $13.4K.
  • Sterling Capital Management first reported a position in Sage Therapeutics in Q4 2015 and held it in 5 quarters.
  • Sterling Capital Management's Sage Therapeutics position peaked at $298K in Q4 2015.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Sterling Capital Management's 13F filing for Q3 2025, filed 12 Nov 2025.